Does sequencing order of antiandrogens in prostate cancer matter?

Affiliations

¹ Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA.
² The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA. eantona1@jhmi.edu.

Comment

Benjamin L Maughan et al. Nat Rev Urol. 2020 Apr.

. 2020 Apr;17(4):197-198.

doi: 10.1038/s41585-020-0289-9.

¹ Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA.
² The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA. eantona1@jhmi.edu.

No abstract available

Comment on

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN. Khalaf DJ, et al. Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11. Lancet Oncol. 2019. PMID: 31727538 Clinical Trial.

1. Khalaf, D. J. et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 20, 1730–1739 (2019). - DOI
1. Terada, N. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. Int. J. Urol. 24, 441–448 (2017). - DOI
1. Brasso, K. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. Eur. Urol. 68, 317–324 (2015). - DOI
1. Maughan, B. L. & Antonarakis, E. S. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin. Pharmacother. 16, 1521–1537 (2015). - DOI
1. Isaacsson Velho, P. et al. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur. Urol. 77, 14–21 (2020). - DOI